1-(4-Pyridyl)piperazine → HCID 18918610, 화합물
반응식
[CH2:1]([O:3][C:4]([CH:6]1[CH2:11][CH2:10][N:9]([C:12](=[O:15])[CH2:13]Br)[CH2:8][CH2:7]1)=[O:5])[CH3:2].[N:16]1[CH:21]=[CH:20][C:19]([N:22]2[CH2:27][CH2:26][NH:25][CH2:24][CH2:23]2)=[CH:18][CH:17]=1>C(#N)C>[N:16]1[CH:21]=[CH:20][C:19]([N:22]2[CH2:23][CH2:24][N:25]([CH2:13][C:12]([N:9]3[CH2:10][CH2:11][CH:6]([C:4]([O:3][CH2:1][CH3:2])=[O:5])[CH2:7][CH2:8]3)=[O:15])[CH2:26][CH2:27]2)=[CH:18][CH:17]=1참가 물질
4
실험 절차
A solution of ethyl-1-(bromoacetyl)piperidin-4-carboxylate (0.84 g, 3 mMoles) in acetonitrile (10 ml) was added dropwise to a stirred solution of 1-(4-pyridyl)piperazine (0.5 g, 3 mMoles) in acetonitrile (20 ml) and the resulting mixture was allowed to stand for 3 hours. The white precipitate was removed by filtration and the mother liquors were concentrated under reduced pressure to give a yellow foam. The foam was purified by chromatography (flash column made with grade III neutral alumina and eluted with a gradient of 0-1% ethanol in dichloromethane) to give the title compound (350 mg) as a colourless oil which was crystallised from cyclohexane to give colourless prisms; mp 102°-104° C.; Microanalysis, found: C,63.5; H,8.1, N, 15.5%; C19H28N4O3 requires C,63.3; H,7.8; N,15.5%; NMR (d6DMSO + CD3COOD): 1.2(t,3H), 1.3-1.7(m,2H), 1.8(m,2H), 2.5-2.8(m,6H), 3.0-3.4(m,3H), 3.6(brs,4H), 3.9(d, 1 H), 4.0(q,2H), 4.2(d, I H), 7. I (d,2H), 8.2(d,2H); m/e 361 (M+H)+.